Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar
about
Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.Integrated pharmacokinetic-Pharmacodynamic (PK/PD) model to evaluate the in vivo antimicrobial activity of Marbofloxacin against Pasteurella multocida in piglets.Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infectionPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MICPharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.Levofloxacin pharmacokinetics in adult cystic fibrosis.Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV.In vitro dissolution and in vivo bioavailability of six brands of ciprofloxacin tablets administered in rabbits and their pharmacokinetic modeling.Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.Identification and characterization of novel cecropins from the Oxysternon conspicillatum neotropic dung beetle.System for real-time monitoring of mutation-in-progress.
P2860
Q33555316-C82DFDBA-C2DC-484F-AAC2-3897DAFE3E1CQ33692694-A80D3500-9A5F-43C8-9BC2-DCBCFE101BF1Q33802390-535B375A-F5C3-41CE-8FB5-07B4CE2820C9Q33895157-C5F7F13E-DA91-4318-AFDE-D83E911D0D3AQ33982098-D203A0BF-F72E-4E7B-9CE6-883FEB239BD6Q34110906-0C805A55-AA07-4095-9112-398FFF53B580Q34297656-A4A6A8AE-5920-4FA7-95C0-8EEBEEFF5E8AQ35127800-82791E92-B8A4-40B8-ACBD-2BEA06D41029Q35139002-76A171EB-886C-4ADD-9A9C-8589B836E03FQ35201049-EB6563AE-7819-4C42-90DA-A8E22C465980Q35637864-E8569329-DA4D-4F27-B847-C455B40B7072Q35985436-B0CF55D4-2C32-443E-8289-949BED4D9786Q36072639-2ACE4121-2B34-4AB0-907F-D9A2919DC69AQ36137356-0D88DA64-F30D-425A-83B7-518459002733Q37568944-4EBD27DC-358E-476E-980B-121406BE2C01Q39740646-ADD1D3C2-2722-485F-835C-CF81C15E4D6EQ39746394-23632B74-3403-4DA2-9A52-BEC99A322F63Q39781591-D57575C1-6F63-4E17-98E5-0F95E1DF4CE0Q39784317-6A76AC82-F00E-49CA-AC83-71C729BE4444Q40153492-77E7E7DF-FB13-479C-8038-B31A3EA12B55Q40621873-1C738FA2-7F4E-4AFD-9C49-354B7853D415Q40733777-A57530E7-4D06-4858-B0D7-A4939862DF53Q40960278-BC150646-E31F-48CD-A6D9-C5D027B1C190Q43820901-429C28D5-6B24-4A90-80E0-44816DAD9B02Q46252054-E239579A-37F2-4F8F-BF65-A84C1E7FA74EQ46734909-5D0FB7EE-7650-40DC-9393-82DE65C31BCE
P2860
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@ast
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@en
type
label
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@ast
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@en
prefLabel
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@ast
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@en
P2093
P2860
P356
P1476
Pharmacokinetic and pharmacody ...... osa for which MICs are similar
@en
P2093
P2860
P304
P356
10.1128/AAC.38.12.2730
P407
P577
1994-12-01T00:00:00Z